BOSTON, June 20,
2024 /PRNewswire/ -- Analysis Group, one of the
largest international economics consulting firms, announces the
promotion of seven vice presidents to managing principal and
principal.
"I'm thrilled to recognize the hard work, creativity, and
dedication of these consultants," said Martha S. Samuelson, CEO and Chairman of
Analysis Group. "Among their many accomplishments, they have
assisted clients across a wide range of services in the US,
Canada, and Europe, including health economics and
outcomes research (HEOR), regulatory submissions, and drug safety
studies; complex securities and valuation analyses; and
high-profile antitrust and cartel litigations. They have also
created focused surveys in support of data privacy, labor
relations, and trademark and intellectual property matters."
New Managing Principals
Keith Betts specializes in the
application of advanced biostatistics techniques in the field of
HEOR. He has broad experience developing research strategies in a
range of disease areas, including endocrinology, immunology,
hematology, neurology, oncology, psychiatry, virology, and women's
health. Dr. Betts has developed and applied new research methods in
the fields of individualized medicine methodology,
meta-analyses/indirect comparisons, causal inference, Bayesian
statistics, missing data problems, and risk prediction. His
expertise includes the design and analysis of clinical trials,
health economics modeling, indirect comparisons/network
meta-analysis, causal inference, psychometrics, survey design, and
retrospective database analyses (including administrative claims,
electronic medical records, and registry data). Dr. Betts's work
includes developing risk-benefit analyses, cost-effectiveness
models, and network meta-analyses for regulatory submission as well
as treatment pattern and burden-of-illness research to support the
launch of emerging products.
Maral DerSarkissian specializes
in the application of epidemiologic methods to real-world evidence
(RWE) generation in support of product registration, post-approval
safety studies, and HEOR. She has served as an expert witness in
litigation and has a wide range of experience in
pharmacoepidemiology, biostatistics, and observational data
analysis, including in studies on causal methods. Dr. DerSarkissian
has provided regulatory and strategic consulting on drug and
medical device registration and conducted RWE studies related to US
Food and Drug Administration (FDA) and European Medicines Agency
(EMA) submissions. She has conducted cost-effectiveness and
comparative effectiveness studies; examined treatment patterns,
drug adherence, health care resource utilization and costs, and
clinical outcomes; assessed direct medical and indirect
productivity costs of a disease burden; and assessed
patient-reported quality of life and the humanistic burden of a
disease. Dr. DerSarkissian has used data from electronic medical
records, clinical trials, commercial insurance claims, patient
surveys, and medical chart review studies in disease areas that
include obesity; HIV/AIDS; cardiovascular diseases; schizophrenia;
autoimmune, neurologic, and rare hereditary disorders; and many
types of cancer. She has presented her research at conferences on
epidemiology and health services, and published articles in a
number of peer-reviewed journals. Dr. DerSarkissian is an adjunct
assistant professor in the epidemiology department at the UCLA
Fielding School of Public Health.
Elyse Swallow specializes in
applying quantitative methods to real-world problems involving
evaluation, decision making, strategy, and public policy in the
health care and social policy sectors. She has more than 15 years
of experience leading data analytics implementation, RWE
generation, regulatory submissions, analytic platform design, and
trial design. Ms. Swallow's expertise includes regulatory-grade
indirect treatment comparisons, survey research, database analyses,
natural history studies, brand strategy, policy evaluation, RWE
development, individualized medicine, and predictive analytics.
Additionally, she has led health and social policy program
evaluations. Ms. Swallow has worked across disease areas, including
obesity, rare diseases, immunology, multiple sclerosis, hematology,
oncology, and renal disease. Her work has been used to inform
regulatory and reimbursement decisions in US and global
markets.
New Principals
Chris Feige specializes in
the areas of finance, securities, and financial markets. He has
worked on and managed a range of securities and valuation projects
in the UK and Europe. Recently,
Mr. Feige led an Analysis Group team serving as economic advisors
to Steinhoff in support of Steinhoff's global securities
settlement. He also managed a team evaluating shareholder reliance
and estimating "but-for" share price in a UK Financial Services and
Markets Act (FSMA) Section 90A litigation matter. Mr. Feige
recently supported experts analyzing the volume of false and spam
accounts on Twitter, Twitter's information security infrastructure,
Twitter's data privacy and compliance with a US Federal Trade
Commission (FTC) consent decree, and share price and valuation
issues on behalf of Twitter in Twitter v. Musk in which
Elon Musk eventually purchased
Twitter at his initial offer price. In cases involving
alleged market manipulation in the foreign exchange
(FX) and IBOR markets, he has analyzed trade data and evaluated
alleged manipulation strategies. Mr. Feige worked on
USA v. Richard Usher, et al., and the Foreign
Exchange Class Antitrust Litigation, analyzing FX trade and
chat data, as well as competition issues; preparing experts for
testimony at trial; and providing data analyses and consulting
support to counsel throughout the projects. He has also worked on a
range of international arbitration cases, including valuation,
damages, and competition analyses. In addition, he has developed
complex valuation models, including discounted cash flow models,
and analyzed asset-backed securities, collateralized debt
obligations, and other securitized products in support of expert
testimony in a number of bankruptcy and damages matters. Mr. Feige
has also worked on a number of international arbitrations valuing
defaulted sovereign debt, expropriated oil fields, and retail
operations.
Rebecca Filsoof applies deep
economic and financial analyses across a broad range of finance and
securities, antitrust, and commercial litigation matters. Her
finance and securities case work has included examining allegations
of securities fraud, evaluating investment compliance
and suitability and compliance with fiduciary duties, assessing
corporate governance, analyzing investment management fees,
analyzing the performance of mortgages and mortgage-backed
securities (MBS), and assessing the appropriateness of class
certification. Ms. Filsoof has supported industry and academic
experts on a variety of topics related to MBS, including due
diligence, loan underwriting, appraisal, trustee duties, and
damages. She has also supported industry experts in addressing
regulatory compliance and banking practices, including issues
related to fraud, Bank Secrecy Act (BSA) and
Anti-Money Laundering (AML) compliance, third-party lending
relationships, and mortgage lending. Ms. Filsoof's antitrust
case work has included analyzing market structure and competitive
dynamics, evaluating the competitive effects of mergers, assessing
the appropriateness of class certification, and estimating
antitrust damages. Her case work has spanned multiple industries,
including financial services, insurance, payment cards, high tech,
aviation, and pharmaceuticals. She has substantial experience in
payments and has supported academic and industry experts in
multiple litigation and consulting engagements involving payment
cards and emerging payment methods.
Emmanuel Frot specializes in the
application of quantitative analyses to competition, litigation,
regulatory, and business intelligence issues. He advises firms in a
wide range of industries, providing economic and econometric
expertise on matters related to mergers, market concentrations,
cartel investigations, and damages. Dr. Frot has performed numerous
economic and econometric analyses in Phase I and Phase II mergers
before the French Competition Authority and the European
Commission, including Veolia Transport/Transdev,
Jardiland/InVivo, Castel/Patriarche, Fnac/Nature
& Découvertes, d'aucy/Triskalia,
Lactalis/Nuova Castelli,
Lactalis/Leerdammer, CMA CGM / Bolloré Logistics,
Canal+/OCS, and Suez/Veolia. Dr. Frot has led case
teams and performed economic analyses in several prominent
horizontal and vertical cartel cases, as well as estimated damages
in antitrust litigation and intellectual property matters. Dr. Frot
has also assisted companies in modeling and implementing changes to
pricing behavior. His reports have been presented to the European
Commission, the French Competition Authority, the Court of Appeals,
the Conseil d'État (France's
highest administrative court), the Tribunal of Commerce of
Paris, and regulators in the
telecommunications, energy, transportation, and
gambling sectors.
Laura O'Laughlin applies her
economic expertise to litigation and non-litigation matters. In the
litigation context, she has served as an expert witness and
testified at trial, and conducts economic analyses and manages case
teams in support of academic and industry experts in a broad range
of matters throughout the US and Canada. She has assisted clients in all phases
of the litigation process, and has supported expert witnesses in
the preparation of reports and other testimony in matters involving
merger reviews, antitrust litigation, competition policy, data
privacy, labor relations, false advertising, finance, valuation,
trademark, intellectual property (IP), and patent infringement. Ms.
O'Laughlin also has experience with allegations of exclusionary
conduct in various industries, including agricultural products,
consumer packaged goods, finance, retail, telecommunications, and
technology. She has developed, administered, and analyzed surveys
in trademark, IP, antitrust, consumer protection, data privacy, and
false advertising matters. In the non-litigation context, Ms.
O'Laughlin uses complex research methods and applies innovative
analytical approaches to provide new insights on the competitive
and market challenges that clients face in managing and expanding
their businesses. She publishes regularly on issues related to
marketing, economics, litigation, and public policy.
To learn more about Analysis Group's capabilities, visit
AnalysisGroup.com
About Analysis Group:
Analysis Group is one of the largest international economics
consulting firms, with more than 1,200 professionals across 14
offices in North America,
Europe, and Asia. Since 1981, we have provided expertise
in economics, finance, health care analytics, and strategy to top
law firms, Fortune Global 500 companies, and government agencies
worldwide. Our internal experts, together with our network of
affiliated experts from academia, industry, and government, offer
our clients exceptional breadth and depth of expertise.
Contact:
Analysis Group
Eric Seymour, 978 273 6049
eric.seymour@analysisgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/analysis-group-announces-promotion-of-seven-vice-presidents-to-managing-principal-and-principal-302172778.html
SOURCE Analysis Group